Is obesity in women protective against osteoporosis?

Diabetes, Metabolic Syndrome and Obesity

Volumn 4, Issue , 2011, Pages 273-282

  Migliaccio, Silvia ^a,b   Greco, Emanuela A ^a   Fornari, Rachele ^a   Donini, Lorenzo M ^a   Lenzi, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

Adipocytes; Body mass index; Bone mineral density; Fat mass; Fractures

Indexed keywords

ADIPONECTIN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ADIPOGENESIS; BODY MASS; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; DISEASE ASSOCIATION; FAT MASS; FEMALE; FRAGILITY FRACTURE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOPOROSIS; PARACRINE SIGNALING; REVIEW; RISK FACTOR;

EID: 84985905232     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S11920     Document Type: Review

References (138)

1. Kado DM, Huang MH, Karlamangla AS, Barrett-Connor E, Greendale GA. Hyperkyphotic posture predicts mortality in older community-dwelling men and women: a prospective study. J Am Geriatr Soc. 2004;52:1662-1667.
2. Rossner S. Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord. 2002;26 Suppl 4:S2-S4.
3. Hu FB. Overweight and obesity in women: health risks and consequences. J Women Health (Larchmt). 2003;12(2):163-172.
4. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
5. Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996;20:1027-1032.
6. Reid IR. Relationships among body mass, its components, and bone. Bone. 2002;31:547-555.
7. NIH. Consensus development panel on osteoporosis. JAMA. 2001;285: 785-795.
8. Cagnacci A, Zanin R, Cannoletta M, Generali M, Caretto S, Volpe A. Menopause, estrogens, progestin, or their combination on body weight and anthropometric measurements. Fertil Steril. 2007;88(6): 1603-1608.
9. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl. 2003;134:18-27.
10. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;8: 37S-41S.
11. Zhao LJ, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 2008;23:17-29.
12. Johansson C, Black D, Johnell O, Oden A, Mellstrom D. Bone mineral density is a predictor of survival. Calcif Tissue Int. 1998;63:190-196.
13. Brown S, Rosen CJ. Osteoporosis. Med Clin North Am. 2003;87: 1039-1063.
14. Goulding A, Jones IE, Taylor RW, Williams SM, Manning PJ. Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy X-ray absorptiometry study. J Pediatr. 2001; 139:509-515.
15. Kveiborg M, Flyvbjerg A, Rattan SI, Kassem M. Changes in the insulinlik growth factor-system may contribute to in vitro agerelate impaired osteoblast functions. Exp Geronto. 2000;35:1061-1074.
16. Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273-278.
17. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endoc Metab. 1992;75:779-782.
18. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988 1;241(4861): 84-86.
19. Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep. 2010;43(8):524-529.
20. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988;241(4861):81-84.
21. Migliaccio S, Davis VL, Gibson MK, Gray TK, Korach KS. Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology. 1992;130(5): 2617-2624.
22. Gomez-Ambrosi J, Rodrıguez A, Catalan V, Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg. 2008;18:1134-1143.
23. Takeda S. Effect of obesity on bone metabolism. Clin Calcium. 2008;18: 632-637.
24. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem. 2006;98:251-266.
25. Fukumoto S, Martrin TJ. Bone as an endocrine organ. Trends Endocrinol Metab. 2009;20(5):230-236.
26. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-75.
27. Melton LJ III, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
28. Mazess RB, Barden HS, Ettinger M, et al. Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner Res. 1987;2:211-219.
29. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: The Framingham study. J Bone Miner Res. 1993;8:567-573.
30. Marcus R, Greendale G, Blunt BA, et al. Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res. 1994;9:1467-1476.
31. Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45-51.
32. Ravn P, Cizza G, Bjarnason NH, Thompson D et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999;14:1622-1627.
33. Khosla S, Atkinson EJ, Riggs BL, Melton LJ, III. Relationship between body composition and bone mass in women. J Bone Miner Res. 1996;11: 857-863.
34. Pluijm SM, Visser M, Smit JH, Popp-Snijders C, Roos JC, Lips P. Determinants of bone mineral density in older men and women: Body composition as mediator. J Bone Miner Res. 2001;16:2142-2151.
35. Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr. 2006;83: 146-154.
36. Greco EA, Fornari R, Rossi F et al. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract. 2010;64(6):817-820.
37. Blum M, Harris SS, Must A, et al. Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int. 2003;73: 27-32.
38. Kim KC, Shin DH, Lee SY, et al. Relation between Obesity and Bone Mineral Density and Vertebral Fractures in Korean Postmenopausal Women. Yonsei Med J. 2010;51(6):857-863.
39. Castro JP, Joseph LA, Shin JJ, et al. Differential effect of obesity on bone mineral density in White, Hispanic and African American women: A cross sectional study. Nutr Metab (Lond). 2005;2:9.
40. Afghani A, Goran MI. Racial differences in the association of subcutaneous and visceral fat on bone mineral content in prepubertal children. Calcif Tissue Int. 2006;79:383-388.
41. Reid IR, Legge M, Stapleton JP, Evans MC, Grey AB. Regular exercise dissociates fat mass and bone density in premenopausal women. J Clin Endocrinol Metab. 1995;80:1764-1768.
42. Reid IR. Therapy of osteoporosis: Calcium, vitamin D, and exercise. Am J Med Sci. 1996;312:278-286.
43. Manson JE, Martin KA. Postmenopausal hormonereplacement therapy. N Engl J Med. 2001;345:34-40.
44. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res. 2001;9:622-626.
45. De Gregorio LH, Lacativa PG, Melazzi AC, Russo LA. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol. 2006;50:793-801.
46. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15: 323-328.
47. Gaillard D, Wabitsch M, Pipy B, Negrel R. Control of terminal differentiation of adipose precursor cells by glucocorticoids. J Lipid Res. 1991;32:569-579.
48. Livingstone DE, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: Tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 2000;141: 560-563.
49. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferatoractivated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002;143:2376-2384.
50. Riche DM, Travis King S. Bone loss and fractures risk associated with thiazolidinedione therapy. Endocrinology. 2007;148(6):2669-2680.
51. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-451.
52. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000; 92:73-78.
53. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res. 2004;12:962-971.
54. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(3-4):222-231.
55. Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM. Molecular Aspects of Adipokine-Bone Interactions. Curr Mol Med. 2010;10(6): 522-532.
56. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. Int J Obes Relat Metab Disord. 1985;9(Suppl 1):83-92.
57. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med. 1994;331: 1056-1061.
58. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689-3698.
59. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci U S A. 2000;97:12729-12734.
60. Cooke PS, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol. 2001;178:147-154.
61. Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: Effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. 2004;89: 61-70.
62. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness, and insulin resistance: Effects of hormone-replacement therapy. Coron Artery Dis. 1998;9: 503-511.
63. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas. 2001;39:125-132.
64. Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: A randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2003;18:333-342.
65. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
66. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology. 2001;2:165-171.
67. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432.
68. Mantzoros CS. The role of leptin in human obesity and disease: A review of current evidence. Ann Intern Med. 1999;130:671-680.
69. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell. 2000;100:197-207.
70. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305-317.
71. Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res. 2004;19:546-551.
72. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int. 1998;63: 456-458.
73. Yamauchi M, Sugimoto T, Yamaguchi T, et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf). 2001;55:341-347.
74. Pasco JA, Henry MJ, Kotowicz MA, et al. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab. 2001;86:1884-1887.
75. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17:1563-1569.
76. Thomas T. Leptin: A potential mediator for protective effects of fat mass on bone tissue. Joint Bone Spine. 2003;70:18-21.
77. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol. 2004;4:295-300.
78. Martin A, de Vittoris R, David V, et al. Leptin modulate both resorption and formation while preventing disuse-induced bone loss in tailsuspended female rats. Endocrinology. 2005;146(8):3652-3659.
79. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2001; 175:405-415.
80. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630-1638.
81. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell. 2005;122:803-815.
82. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434: 514-520.
83. Karsenty G. Convergence between bone and energy homeostases: Leptin regulation of bone mass. Cell Metab. 2006;4:341-348.
84. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-770.
85. Wisse BE, Schwartz MW. Role of melanocortins in control of obesity. Lancet. 2001;358:857-859.
86. Herzog H. Neuropeptide Y and energy homeostasis: Insights from Y receptor knockout models. Eur J Pharmacol. 2003;480:21-29.
87. Liu YJ, Araujo S, Recker RR, Deng HW. Molecular and genetic mechanisms of obesity: Implications for future management. Curr Mol Med. 2003;3:325-340.
88. Sainsbury A, Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A. 2002;99:8938-8943.
89. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109:915-921.
90. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adiposederived protein Acrp30. J Clin Invest. 2001;108:1875-1881.
91. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
92. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842-849.
93. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520-526.
94. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309:99-109.
95. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
96. Lenchik L, Register TC, Hsu FC et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646-651.
97. Jurimae J, Rembel K, Jurimae T, Rehand M. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res. 2005;37:297-302.
98. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006;99(3): 824-834.
99. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273-2282.
100. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
101. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
102. Berthier MT, Paradis AM, Tchernof A. The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet. 2003;48:14-19.
103. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
104. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: Synergy with dexamethasone. Cytokine. 2000;12:613-621.
105. Rodan GA. Introduction to bone biology. Bone. 1992;13(Suppl 1): S3-S6.
106. Dodds RA, Merry K, Littlewood A, Gowen M. Expression of mRNA for IL1 beta, IL6 and TGF beta 1 in developing human bone and cartilage. J Histochem Cytochem. 1994;42:733-744
107. Taguchi Y, Yamamoto M, Yamate T, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians. 1998;110:559-574.
108. Franchimont N, Wertz S, Malaise M 2005 Interleukin-6: An osteotropic factor influencing bone formation? Bone 37:601-606.
109. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. 2004 Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest. 113:379-389.
110. Sims NA, Jenkins BJ, Quinn JM, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest. 2004;113:379-389.
111. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol. 2005;25(10):2062-2068.
112. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med. 2009 Aug;8(41):55-60.
113. Akune T, Ohba S, Kamekura S, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846-855.
114. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferatoractivated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996;50: 1087-1094.
115. Rodriguez JP, Montecinos L, Rios S, Reyes P, Martinez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem. 2000;79:557-565.
116. Sekiya I, Larson BL, Vuoristo JT, Cui JG, Prockop DJ. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J Bone Miner Res. 2004;19:256-264.
117. Aubin JE, Bone stem cells. J Cell Biochem.1998;Suppl 30-31:73-82.
118. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadalmetabolic-atherogenicdisease and aging connection. Med Hypotheses. 2001;56:702-708.
119. Martin RB, Zissimos SL. Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone. 1991;12: 123-131.
120. Martin RB, Chow BD, Lucas PA. Bone marrow fat content in relation to bone remodeling and serum chemistry in intact and ovariectomized dogs. Calcif Tissue Int. 1990;46:189-194.
121. Cheleuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status. J Clin Endocrinol Metab.1998;83:2043-2051.
122. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3: 379-389.
123. Kajkenova O, Lecka-Czernik B, Gubrij I, et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6: a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res. 1997;12:1772-1779.
124. Duque G, Macoritto M, Kremer R. Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity. Biogerontology. 2004;5:421-429.
125. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.
126. Ross SE, Erickson RL, Gerin I. Microarray analyses during adipogenesis: Understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor {alpha} in adipocyte metabolism. Mol Cell Biol. 2002;22:5989-5999.
127. Bennett CN, Ross SE, Longo KA. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002;277:30998-31004.
128. Gong Y, Slee RB, Fukai N. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107: 513-523.
129. Boyden LM, Mao J, Belsky J. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346: 1513-1521.
130. Kato M, Patel MS, Levasseur R. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157:303-314.
131. Little RD, Carulli JP, Del Mastro RG. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bonemass trait. Am J Hum Genet. 2002;70:11-19.
132. Bennett CN, Longo KA, Wright WS Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005;102: 3324-3329.
133. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylationdefective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem. 2004;279:45020-45027.
134. Zhou S, Eid K, Glowacki J. Cooperation between TGFbeta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res. 2004;19:463-470.
135. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res. 2004;19:841-852.
136. Kindblom JM, Gevers EF, Skrtic SM. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone. 2005;36:607-616.
137. Kajkenova O, Lecka-Czernik B, Gubrij I. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res. 1997;12:1772-1779.
138. Duque G, Macoritto M, Dion N, Ste-Marie LG, Kremer R. 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab. 2005;288:E723-E730.